{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:43:50Z","timestamp":1784126630625,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100293","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T06:58:49Z","timestamp":1634885929000},"page":"100293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI\/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO"],"prefix":"10.1016","volume":"6","author":[{"given":"D.","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100293_bib1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100293_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw052","article-title":"FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials","volume":"27","author":"Cremolini","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","volume":"38","author":"Cremolini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib5","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100293_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","article-title":"Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy","volume":"100","author":"Shayne","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100293_bib7","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib8","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2352-3026(20)30067-3","article-title":"Longitudinal toxicity over time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial","volume":"7","author":"Thanarajasingam","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2021.100293_bib9","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11523-015-0400-y","article-title":"A\u00a0review of clinical studies and practical guide for the administration of triplet chemotherapy regimens with bevacizumab in first-line metastatic colorectal cancer","volume":"11","author":"Loupakis","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","article-title":"Advances in the treatment of neutropenia","volume":"3","author":"Dale","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.esmoop.2021.100293_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100293_bib13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib14","first-page":"529","article-title":"Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?","volume":"18","author":"Aapro","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2021.100293_bib15","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","article-title":"First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy","volume":"16","author":"Silber","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1078155201jp084oa","article-title":"Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature","volume":"7","author":"Wilson-Royalty","year":"2001","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.esmoop.2021.100293_bib17","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1200\/jco.2004.22.90140.6125","article-title":"Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy","volume":"22","author":"Wolff","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100293_bib18","first-page":"147","article-title":"A\u00a0multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study","volume":"17","author":"Oki","year":"2018","journal-title":"Clin Col Cancer"},{"key":"10.1016\/j.esmoop.2021.100293_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.18632\/oncotarget.26626","article-title":"Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: a multicenter retrospective study","volume":"10","author":"Ogata","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100293_bib20","doi-asserted-by":"crossref","first-page":"18811","DOI":"10.18632\/oncotarget.24702","article-title":"A\u00a0phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11","volume":"9","author":"Satake","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100293_bib21","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.18632\/oncotarget.23559","article-title":"DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer","volume":"9","author":"Cremolini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100293_bib22","first-page":"581","article-title":"DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan","volume":"80","author":"Falvella","year":"2015","journal-title":"Br J Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:58Z","timestamp":1761855958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2059702921002556"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100293","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI\/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100293"}}